BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.19
-0.21 (-2.84%)
Apr 16, 2025, 4:00 PM EDT - Market closed
BioCryst Pharmaceuticals Revenue
In the year 2024, BioCryst Pharmaceuticals had annual revenue of $450.71M with 36.00% growth. BioCryst Pharmaceuticals had revenue of $131.53M in the quarter ending December 31, 2024, with 40.83% growth.
Revenue (ttm)
$450.71M
Revenue Growth
+36.00%
P/S Ratio
3.31
Revenue / Employee
$777,090
Employees
580
Market Cap
1.50B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 450.71M | 119.30M | 36.00% |
Dec 31, 2023 | 331.41M | 60.59M | 22.37% |
Dec 31, 2022 | 270.83M | 113.66M | 72.31% |
Dec 31, 2021 | 157.17M | 139.36M | 782.38% |
Dec 31, 2020 | 17.81M | -31.02M | -63.53% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BCRX News
- 12 days ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 14 days ago - BioCryst to Present at Upcoming Investor Conference - GlobeNewsWire
- 7 weeks ago - BioCryst: Orladeyo's Expansion Is Just Getting Started - Seeking Alpha
- 7 weeks ago - BioCryst: Hold Steady As Orladeyo Builds, But Competition Heats Up - Seeking Alpha
- 7 weeks ago - BioCryst: Upgrading On Strong 2024 Orladeyo Sales, But I Remain Skeptical - Seeking Alpha
- 7 weeks ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - BioCryst Pharmaceuticals Unveils Latest Trial Data, Reports Mixed Q4 Earnings - Benzinga
- 7 weeks ago - BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones - GlobeNewsWire